If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology GSK to invest up to £50 million in collaboration to generate key insights ...

Rising awareness, innovative therapies, and evolving treatment options drive this growth.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when drugs were found to be harmful.

Belrestotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck ...